Tags

Type your tag names separated by a space and hit enter

Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis.
Int J Cardiol. 2009 Nov 12; 137(3):282-8.IJ

Abstract

BACKGROUND

The effects of angiotensin-II type 1 receptor blockers (ARBs) on the treatment of hypertension, heart failure, and other cardiovascular diseases have been confirmed extensively. However, recent studies have emphasized the nonhemodynamic effects of these drugs. The purpose of this study was to investigate the effects of ARBs on the development of experimental autoimmune myocarditis (EAM), and to clarify the mechanisms involved.

METHODS

EAM model was induced in Lewis rats by injection of porcine cardiac myosin subcutaneously. We administered valsartan (a new ARB) to rats with EAM and measured blood pressure regularly. Echocardiography was performed to examine the cardiac function and heart structure of the rats. The severity of myocarditis was detected by histopathological evaluation. We evaluated antigen-specific T-cell proliferation responses to cardiac myosin by the lymphocyte proliferation assay and measured serum levels of Th1 and Th2 cytokines by enzyme-linked immunosorbent assay.

RESULTS

There was no significant difference in the blood pressure (BP) level between the groups and cardiac function of valsartan-treated rats was significantly improved compared with untreated rats. Valsartan markedly reduced the severity of myocardial lesions and suppressed lymphocyte proliferation in rats immunized with myosin. After drug administration, Th1 cytokines (IFN-gamma and IL-2) were significantly down-regulated, while Th2 cytokines (IL-4 and IL-10) were detected to undergo up-regulation.

CONCLUSIONS

The results suggest that valsartan can ameliorate EAM independent of BP-lowering effects. Some of the beneficial effects of ARBs may be due to their immunomodulatory reactions in the modification of helper T-cell balance.

Authors+Show Affiliations

Department of Cardiology, Provincial Hospital Affiliated to Shandong University, 324 Jingwu Weiqi Road, Jinan, 250021, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19896742

Citation

Liu, Xuefei, et al. "Effects of angiotensin-II Receptor Blockers On Experimental Autoimmune Myocarditis." International Journal of Cardiology, vol. 137, no. 3, 2009, pp. 282-8.
Liu X, Zhu X, Wang A, et al. Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis. Int J Cardiol. 2009;137(3):282-8.
Liu, X., Zhu, X., Wang, A., Fan, H., & Yuan, H. (2009). Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis. International Journal of Cardiology, 137(3), 282-8. https://doi.org/10.1016/j.ijcard.2009.09.540
Liu X, et al. Effects of angiotensin-II Receptor Blockers On Experimental Autoimmune Myocarditis. Int J Cardiol. 2009 Nov 12;137(3):282-8. PubMed PMID: 19896742.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis. AU - Liu,Xuefei, AU - Zhu,Xinglei, AU - Wang,Aiying, AU - Fan,Hui, AU - Yuan,Haitao, Y1 - 2009/11/06/ PY - 2009/05/26/received PY - 2009/08/18/revised PY - 2009/09/22/accepted PY - 2009/11/10/entrez PY - 2009/11/10/pubmed PY - 2010/2/27/medline SP - 282 EP - 8 JF - International journal of cardiology JO - Int J Cardiol VL - 137 IS - 3 N2 - BACKGROUND: The effects of angiotensin-II type 1 receptor blockers (ARBs) on the treatment of hypertension, heart failure, and other cardiovascular diseases have been confirmed extensively. However, recent studies have emphasized the nonhemodynamic effects of these drugs. The purpose of this study was to investigate the effects of ARBs on the development of experimental autoimmune myocarditis (EAM), and to clarify the mechanisms involved. METHODS: EAM model was induced in Lewis rats by injection of porcine cardiac myosin subcutaneously. We administered valsartan (a new ARB) to rats with EAM and measured blood pressure regularly. Echocardiography was performed to examine the cardiac function and heart structure of the rats. The severity of myocarditis was detected by histopathological evaluation. We evaluated antigen-specific T-cell proliferation responses to cardiac myosin by the lymphocyte proliferation assay and measured serum levels of Th1 and Th2 cytokines by enzyme-linked immunosorbent assay. RESULTS: There was no significant difference in the blood pressure (BP) level between the groups and cardiac function of valsartan-treated rats was significantly improved compared with untreated rats. Valsartan markedly reduced the severity of myocardial lesions and suppressed lymphocyte proliferation in rats immunized with myosin. After drug administration, Th1 cytokines (IFN-gamma and IL-2) were significantly down-regulated, while Th2 cytokines (IL-4 and IL-10) were detected to undergo up-regulation. CONCLUSIONS: The results suggest that valsartan can ameliorate EAM independent of BP-lowering effects. Some of the beneficial effects of ARBs may be due to their immunomodulatory reactions in the modification of helper T-cell balance. SN - 1874-1754 UR - https://www.unboundmedicine.com/medline/citation/19896742/Effects_of_angiotensin_II_receptor_blockers_on_experimental_autoimmune_myocarditis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0167-5273(09)01483-1 DB - PRIME DP - Unbound Medicine ER -